Selecting effective antisense reagents on combinatorial oligonucleotide arrays

Nature Biotechnology
N MilnerE M Southern

Abstract

An array of 1,938 oligodeoxynucleotides (ONs) ranging in length from monomers to 17-mers was fabricated on the surface of a glass plate and used to measure the potential of oligonucleotide for heteroduplex formation with rabbit beta-globin mRNA. The oligonucleotides were complementary to the first 122 bases of mRNA comprising the 5' UTR and bases 1 to 69 of the first exon. Surprisingly few oligonucleotides gave significant heteroduplex yield. Antisense activity, measured in a RNase H assay and by in vitro translation, correlated well with yield of heteroduplex on the array. These results help to explain the variable success that is commonly experienced in the choice of antisense oligonucleotides. For the optimal ON, the concentration required to inhibit translation by 50% was found to be five times less than for any other ON. We find no obvious features in the mRNA sequence or the predicted secondary structure that can explain the variation in heteroduplex yield. However, the arrays provide a simple empirical method of selecting effective antisense oligonucleotides for any RNA target of known sequence.

References

Oct 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·J A JaegerM Zuker
Dec 24, 1996·Proceedings of the National Academy of Sciences of the United States of America·B P MoniaD Fabbro
Jul 1, 1996·Nature Biotechnology·R W WagnerB C Froehler

❮ Previous
Next ❯

Citations

Aug 10, 1999·Biotechnology and Bioengineering·S P WaltonC M Roth
Jun 28, 2000·FEBS Letters·E V KostenkoM A Zenkova
Jul 13, 2001·Pharmacology & Therapeutics·C J Wraight, P J White
Aug 24, 1999·Pharmacology & Therapeutics·S R CooperN M Dean
Jun 1, 2001·Journal of Biochemical and Biophysical Methods·E ZamaratskiJ Chattopadhyaya
Jan 19, 2000·Trends in Pharmacological Sciences·K J Myers, N M Dean
Mar 8, 2002·Trends in Neurosciences·P Estibeiro, J Godfray
May 12, 2000·Biochimica Et Biophysica Acta·N Agarwal, A M Gewirtz
May 12, 2000·Biochimica Et Biophysica Acta·J Summerton
Apr 6, 1999·Trends in Biotechnology·D J Graves
Oct 18, 2000·Advanced Drug Delivery Reviews·S AkhtarP Sayyed
Oct 18, 2000·Advanced Drug Delivery Reviews·M Sohail, E M Southern
Jul 18, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Rolf A Stahel, Uwe Zangemeister-Wittke
Oct 24, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·L SmithJ W Jaroszewski
Jan 16, 1999·Current Opinion in Biotechnology·A WatsonS Balasubramanian
Sep 11, 2002·Neuromuscular Disorders : NMD·G DicksonI R Graham
Jun 6, 2003·Bioorganic & Medicinal Chemistry·Atsushi MaharaAkira Murakami
Jul 18, 2000·Journal of the American College of Surgeons·D W GreenJ A Drebin
Mar 21, 2001·Drug Discovery Today·M D. HughesS Akhtar
Aug 6, 1998·Current Opinion in Chemical Biology·S C Case-GreenE M Southern
Nov 9, 2002·The Lancet Oncology·Burkhard Jansen, Uwe Zangemeister-Wittke
Jun 1, 1997·Nature Biotechnology·F C Szoka
Feb 14, 1998·Nature Genetics·J G HaciaF S Collins
Feb 18, 2006·Nature Reviews. Genetics·Jörg D Hoheisel
Apr 3, 2007·Nature Structural & Molecular Biology·Dang LongYe Ding
Nov 25, 2000·British Journal of Haematology·D A Fennell, F E Cotter
Apr 16, 2003·European Journal of Biochemistry·Jens Kurreck
Sep 22, 2000·Nucleosides, Nucleotides & Nucleic Acids·V PetyukV Vlassov
Jul 22, 1998·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·Q LiuL M Smith
May 21, 1998·Antisense & Nucleic Acid Drug Development·N M DeanJ Holmlund
Jul 21, 1998·Antisense & Nucleic Acid Drug Development·A D Branch
Aug 27, 1999·Antisense & Nucleic Acid Drug Development·S SeidmanH Soreq
Oct 6, 2005·Oligonucleotides·Rosel Kretschmer-Kazemi FarGeorg Sczakiel
Feb 28, 1998·Nucleic Acids Research·T B CampbellM Hagen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.